DevPro Biopharma Celebrates Five Years of Clinical Innovation
JULY 2, 2025 – DevPro Biopharma, a leading provider of clinical development solutions for the biopharmaceutical industry, is proud to announce its five-year anniversary, marking a significant milestone in the company’s journey to identify and develop safe and effective therapies worldwide.
Since its founding in July 2020, DevPro has developed cutting-edge respiratory products, supported multiple clinical trials across all phases, and built strong partnerships with emerging biotech and established pharmaceutical companies alike.
Co-Founder and CEO Colin Reisner, MD, has over three decades of experience in internal medicine, allergies, and immunology. “Our mission has always been to design, develop, and deliver molecules into medicines,” said Reisner. “Our unique model brings transformative medicines to patients faster. This milestone is not only a celebration of our accomplishments, but a testament to the impact we have had on global social and environmental concerns.”
The company set out by creating a world-class development team, established by former Pearl Therapeutics and AstraZeneca executives. The team has collectively contributed to more than 50 approved products or label expansions spanning multiple therapeutic areas across the globe over the past 30 years, including four combination products from concept to successful registration trial. The seasoned DevPro team also includes an advisory council of notable business and scientific leaders.
“We continually reimagine clinical trial development and execution by leveraging our partnerships and operations,” said Co-Founder and COO Earl St. Rose. “We bring deep clinical, scientific, and regulatory experience to every project, and it’s why we are trusted with complex trial design and execution.”
DevPro Biopharma’s 5-year anniversary highlights the company’s rapid growth, reputation for high-quality clinical execution, and unwavering commitment to excellence. Reisner added, “As we look to the future, we remain focused on improving quality, minimizing risk, accelerating timelines, and saving money for our partners and patients. We’re proud to be at the forefront of respiratory research.”
###